Approvals and Studies Announced for Datroway in Q1 2026 

Market Highlights

  • Press releases announced approval status updates for breast cancer. AstraZeneca and Daiichi Sankyo also discussed recent developments for their financial results, portfolios, and pipelines.

  • Readers were informed that the first patient was dosed in a lung cancer study, and touted updated NCCN Guidelines recommending Datroway.

Questions about this SnapShot or other markets?

U.S. MARKETS

Christine Alongi
alongi@dtwresearch.com

GLOBAL MARKETS

Robin Cefalo
cefalo@dtwresearch.com

SOCIAL MEDIA MARKETS

Andrew Carney
carney@dtwresearch.com